Actively Recruiting
Cannabidiol and Older Adult Cannabis Users
Led by University of Colorado, Boulder · Updated on 2024-05-08
385
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.
CONDITIONS
Official Title
Cannabidiol and Older Adult Cannabis Users
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 60 years of age
- Able to provide informed consent
- Must have used a cannabis product at least once with no negative effects
- Must not have been regularly using any cannabis products (<3x/month) in the last 6 months
- Female participants must be postmenopausal
- Liver function tests (ALT and AST) must show levels no greater than 2x the upper normal limits for age
- Must be currently taking medication(s) for pain, sleep, and/or mood
You will not qualify if you...
- Blood alcohol level > 0 at screening (to sign consent form)
- Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs
- Past or current diagnosis, or family history of diagnosis of psychosis
- Current use of anti-epileptic medications (e.g. clobazam, sodium valproate)
- Current use of medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide)
- Current use of antipsychotic medications
- Currently undergoing chemotherapy (to prevent drug interactions)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado at Boulder
Boulder, Colorado, United States, 80309
Actively Recruiting
Research Team
K
Kyle A Chrystal, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here